Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.
10 United States sites
3 to 21 Years
Phase 3
This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD).
2 United States sites
12 to 35 Years
Phase 1/Phase 2
This study is a first-in-human, single-arm, open-label Phase I/II study of GPH101 in approximately 15 participants, diagnosed with severe Sickle Cell Disease.
1 United States site
12 to 40 Years
Phase 1/Phase 2
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of FT-4202 and test how well FT-4202 works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
9 United States sites
12 to 65 Years
Phase 2/Phase 3
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease .
10 United States sites
4 Tunisia sites
3 Lebanon sites
1 Greece site
1 Italy site
1 Netherlands site
1 Oman site
18 to 65 Years
HbSS
Phase 2
The overall purpose of this proposed study is to improve management of vaso-occlusive episodes (VOEs) in adult EDs.
8 United States sites
18 to 45 Years
SS, SC
N/A
The application of experimental hematopoietic cell transplantation (HCT) therapy in sickle-cell disease (SCD) must strike a balance between the underlying disease severity and the possibility of a direct benefit of the treatment, particularly in pediatric populations.
2 United States sites
5 to 30 Years
Phase 1
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.
2 United States sites
1 Canada site
18 to 65 Years
Phase 1/Phase 2
This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease.
1 United States site
18 to 45 Years
HbSS
Phase 1
This project proposes to develop, test and evaluate targeted interventions to improve clinical provider prescribing of and patient adherence to hydroxyurea (HU).
8 United States sites
15 to 45 Years
SS, SC
N/A
